Assignment Prompt & Instructions
use the attached info
ENSURE TO USE THE RUBRICS FOR FULL POINT
**files (4)**
– ## pharmwk1asign.docx
– ## template.docx
– ## GOALTotalCholesterol.docx
– ## pharmwk1rubric.docx
**## pharmwk1asign.docx**
ASSIGNMENT: CARDIOVASCULAR SYSTEM PATIENT CASE, PART 1
This Assessment invites you to apply your pharmacological knowledge to a real-world scenario. You will be tasked with developing a
**personalized medication plan**, considering factors such as genetics, age, ethnicity, and pathophysiological changes. This assignment emphasizes the importance of ethical and legal considerations in advanced practice, requiring you to
**justify your clinical decisions** and
**write complete medication orders**. The study questions and required readings will serve as essential tools to guide your analysis and support your evidence-based approach.
**Level 1: No AI Permitted**
· AI tools may
**not** be used at any stage
· Common for clinical documentation or performancebased work
RESOURCES
Be sure to review the Learning Resources before completing this assessment.
[Required Resources](https://waldenu.instructure.com/courses/230368/assignments/3290061?module_item_id=9903127)
**To prepare:**
· Complete the Cardiovascular System Patient Case scenario.
· Utilize course resources, clinical practice guidelines, and scholarly sources published within the past 5 years to assist you in completing the cardiovascular system patient case.
· Download the Patient Case Study Template.
BY SUNDAY OF WEEK 1
Complete the Patient Case Study Template. The template will include the following:
· Describe and outline the specific medications you would prescribe for the provided patient. In your description, be sure to consider factors such as genetics, gender, ethnicity, age, behavior, and/or possible pathophysiological changes due to disease (e.g., renal failure, heart failure, liver failure).
· Discuss the ethical and legal considerations of the personalized plan.
· Write a complete medication order for all medications prescribed.
· Use and cite at least three scholarly sources published within the past 5 years, and follow the APA format for in-text citations and reference list.
## image1.png
## image2.png
**## template.docx**
## Patient Case Study Template
### 1. Patient Profile
·
**Age:**
·
**Gender:**
·
**Ethnicity:**
·
**Relevant Genetics (if available):**
·
**Behavioral Factors (e.g., smoking, alcohol, adherence):**
·
**Relevant Medical History:**
·
**Current Diagnoses:**
·
**Pathophysiological Changes (e.g., renal, heart, or liver failure):**
### 2. Medication Plan
Describe and outline the specific medications you would prescribe for the patient. In your description, be sure to consider genetics, gender, ethnicity, age, behavioral factors, and possible pathophysiological changes due to disease.
·
**Medication Name:**
·
**Dosage and Route:**
·
**Frequency:**
·
**Rationale for Selection (including patient-specific factors):**
·
**Potential Drug Interactions or Contraindications:**
·
**Monitoring Parameters:**
### 3. Ethical and Legal Considerations
Discuss any ethical and legal considerations related to the personalized medication plan, including informed consent, patient autonomy, cultural sensitivity, and compliance with relevant laws and guidelines.
### 4. Complete Medication Order
Write a complete and clear medication order for all prescribed medications. Ensure the order includes medication name, dose, route, frequency, and any special instructions.
·
**Medication Name:**
·
**Dose:**
·
**Route:**
·
**Frequency:**
·
**Special Instructions:**
### 5. References
Include at least three scholarly sources (published within the last 5 years) to support your plan. Use proper APA format for both in-text citations and the reference list.
·
**In-text citations example:** (Author, Year)
·
**Reference list example:** Author, A. A., & Author, B. B. (Year). Title of article.
_Title of Journal, volume number_(issue number), page range. [URL]>
**## GOALTotalCholesterol.docx**
**GOAL Total Cholesterol**
The following information will help you understand the critical roles of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) in cardiovascular health. By exploring the mechanisms by which LDL contributes to atherosclerosis and the protective functions of HDL, you will gain insight into the clinical significance of lipid management and current guideline perspectives.
**Why is LDL Harmful?**
The callouts in the picture below explain why LDL is harmful.
**LDL and HDL: Clinical Risk, Guidelines, and Cardiovascular Implications**
Elevated low-density lipoprotein (LDL) levels are directly and dose-dependently associated with increased risk of atherosclerotic cardiovascular disease (ASCVD), prompting clinical guidelines to emphasize aggressive LDL reduction, particularly in high-risk populations. In contrast, high-density lipoprotein (HDL) supports cardiovascular health by facilitating reverse cholesterol transport, removing excess cholesterol from peripheral tissues and promoting its excretion, thereby offering a protective effect against atherosclerosis.
**Clinical Risk Relationship**
Direct, dose-dependent relationship:
· Higher LDL = higher ASCVD risk
· No known “safe” lower threshold
Each ~39 mg/dL (1 mmol/L) LDL reduction lowers major CV events by ~20–25%
**Guideline Perspective**
· ACC/AHA focuses on percent LDL reduction, not absolute targets
· High-risk patients (diabetes, smoking, hypertension, obesity) benefit from aggressive LDL lowering
· LDL ≥190 mg/dL is considered severe hypercholesterolemia
· High-Density Lipoprotein (HDL) participates in reverse cholesterol transport.
**Understanding HDL**
High-density lipoprotein (HDL) plays a crucial role in cardiovascular health by removing cholesterol from arterial walls and macrophages, transporting it back to the liver for excretion, a process known as reverse cholesterol transport. Beyond cholesterol removal, HDL exhibits anti-inflammatory, antioxidant, and endothelial-protective effects, contributing to its atherprotective properties. Clinically, low HDL is recognized as an independent risk marker for atherosclerotic cardiovascular disease (ASCVD), with thresholds defined as less than 40 mg/dL in men and less than 50 mg/dL in women. Low HDL often coexists with other risk factors such as insulin resistance, smoking, obesity, and metabolic syndrome, further elevating ASCVD risk.
PROTECTIVE FUNCTIONS OF HDL
LOW HDL AND RISK
· Removes cholesterol from arterial walls and macrophages
· Transports cholesterol back to the liver for excretion
· Has:
· Anti-inflammatory effects
· Antioxidant properties
· Endothelial-protective actions
Continued
**Cholesterol Management in Patients with High CHD Risk**
In patients with high-risk coronary heart disease (CHD), effective cholesterol management is critical to reducing atherosclerotic cardiovascular disease (ASCVD) risk. St. John’s wort, a commonly used herbal supplement, is a potent inducer of the CYP3A4 enzyme and P-glycoprotein, which significantly increases the metabolism of statins such as atorvastatin, simvastatin, and lovastatin. This induction leads to reduced serum statin concentrations, diminished LDL-lowering efficacy, and a failure to achieve recommended LDL reduction goals. As a result, residual ASCVD risk remains elevated despite apparent adherence to statin therapy. Clinicians should be vigilant about potential drug–herb interactions, especially in high-risk patients, and routinely assess supplement use to ensure optimal statin effectiveness and cardiovascular outcomes.
**CYP3A4 Enzyme Induction → Reduced Statin Levels**
St. John’s wort is a potent inducer of hepatic and intestinal CYP3A4 and P-glycoprotein.
**Statins Affected**
· Atorvastatin
· Simvastatin
· Lovastatin
**Clincal Effect**
· ↑ CYP3A4 activity → increased statin metabolism
· ↓ Statin serum concentration
· ↓ LDL-lowering efficacy
· Failure to reach LDL reduction goals
· ↑ Residual ASCVD risk despite “adherence”
This interaction is especially dangerous in
**high-risk patients**, where aggressive LDL lowering is essential.
Continued
Continued
**Patient Case Scenario**
Complete the patient case scenario by answering clinical questions regarding how you might treat this patient. Use the information and resources presented throughout this activity to help you determine your choices.
Continued
**Case Wrap-Up: Key Takeaways for NP Students (ACC/AHA Focus)**
**LDL Cholesterol Drives ASCVD Risk**
·
**LDL is causal** in atherosclerosis; lowering LDL reduces MI and stroke risk
· In adults
**40–75 with diabetes**, LDL management is
**mandatory**, not optional
·
**High-intensity statin therapy** is indicated when diabetes is accompanied by additional risk factors (e.g., smoking, hypertension, obesity)
**Statin Intensity Matters**
· High-intensity statins aim for
**≥50% LDL reduction**
· Moderate-intensity statins are
**insufficient** in high-risk patients
· Choice of statin should account for
**drug–drug and drug–supplement interactions**
**Herbal Supplements Are Not Benign**
·
**St. John’s wort induces CYP3A4**, reducing effectiveness of several statins
· Reduced statin exposure
**= loss of cardiovascular protection**
· Always ask about
**OTC and herbal products**
**Important Note:**
Supplements can cause therapeutic failure, not just toxicity.
**HDL Is a Risk Marker, Note a Treatment Plan**
· Low HDL increases ASCVD risk but
**raising HDL pharmacologically does not improve outcomes**
· Focus on:
· LDL lowering
· Smoking cessation
· Exercise and weight loss
**Smoking is the Most Dangerous Modifiable Risk Factor**
· Smoking:
· Accelerates atherosclerosis
· Lowers HDL
· Increases LDL oxidation
· Statins cannot fully offset the harm of tobacco use
**Board Tip:** Smoking cessation may reduce ASCVD risk more than any single medication.
**Diabetes = Cardiovascular Disease Risk Equivalent**
· Diabetes dramatically increases ASCVD risk even in younger patients
· GLP-1 receptor agonists (e.g., liraglutide) provide
**cardiovascular benefit**
· Aggressive risk factor modification is required early
**BMI and Lifestyle Changes Are Part of Pharmacotherapy**
· Obesity worsens:
· Dyslipidemia
· Hypertension
· Insulin resistance
· Modest weight loss (5–10%) improves lipid and glycemic control
**Monitoring Is a Safety and Effectiveness Tool**
· Lipid panels are used to assess
**response and adherence**, not just diagnosis
· Follow-up at
**4–12 weeks** after statin initiation is essential
END OF ACTIVITY
## image1.jpeg
## image2.jpeg
**## pharmwk1rubric.docx**
**NURS_6521_Module1_Assignment1_Rubric**
| | | |
| — | — | — |
| NURS_6521_Module1_Assignment1_Rubric |
| **Criteria** | **Ratings** | **Pts** |
| This criterion is linked to a Learning OutcomeMedication Selection and Personalization | **15 to >13.5 ptsExcellent** Medication choices are thoroughly justified with clear, evidencebased rationale. Demonstrates strong integration of genetics, gender, ethnicity, age, behavior, and pathophysiological factors (e.g., renal/hepatic/cardiac impairment). Personalization is comprehensive and clinically sound.<br> <br>**13.5 to >11.9 ptsGood** Medication choices are appropriate and supported with rationale. Most personalized patient factors are considered, though depth may be limited.<br> <br>**11.9 to >10.4 ptsFair** Medication choices are partially justified; rationale may be vague or incomplete. Limited personalization or missing key factors.<br> <br>**10.4 to >0 ptsPoor** Medication choices are unclear, inappropriate, or unsupported. No meaningful personalization present. | 15 pts |
| This criterion is linked to a Learning OutcomeEthical and Legal Considerations | **12.5 to >11.1 ptsExcellent** Demonstrates sophisticated insight into ethical and legal implications (e.g., prescriptive authority, informed consent, cultural humility, scope of practice). Connections to the case are strong and wellsupported.<br> <br>**11.1 to >9.9 ptsGood** Addresses relevant ethical and legal issues with appropriate detail; some application to the case is evident.<br> <br>**9.9 to >8.6 ptsFair** Mentions ethical and legal considerations, but discussion lacks depth or clear application to the case.<br> <br>**8.6 to >0 ptsPoor** Ethical and legal considerations are inaccurate, missing, or irrelevant. | 12.5 pts |
| This criterion is linked to a Learning OutcomeMedication Orders (Accuracy and Completeness) | **12.5 to >11.1 ptsExcellent** All medication orders are complete, accurate, and written in correct clinical format (drug, dose, route, frequency, duration, special instructions). Orders reflect safe, evidencebased prescribing.<br> <br>**11.1 to >9.9 ptsGood** Orders are mostly correct with minor errors in formatting or specificity. Safe and generally appropriate.<br> <br>**9.9 to >8.6 ptsFair** Orders include several formatting, dosing, or instruction errors. Some concerns about safety or completeness.<br> <br>**8.6 to >0 ptsPoor** Orders are incomplete, incorrect, unsafe, or not in clinical format. | 12.5 pts |
| This criterion is linked to a Learning OutcomeCritical Analysis and Source Integration | **2.5 to >2.2 ptsExcellent** Demonstrates strong critical analysis and synthesis of course concepts and module readings.<br> <br>**2.2 to >1.9 ptsGood** Demonstrates sufficient critical analysis and synthesis of course concepts and module readings.<br> <br>**1.9 to >1.7 ptsFair** Demonstrates minimal critical analysis and synthesis of course concepts and module readings.<br> <br>**1.7 to >0 ptsPoor** Lacks critical analysis and/or synthesis of course concepts and module readings. | 2.5 pts |
| This criterion is linked to a Learning OutcomeNumber and Quality of Sources | **2.5 to >2.2 ptsExcellent** Uses 3 peer-reviewed scholarly sources.<br> <br>**2.2 to >1.9 ptsGood** Uses 2 number of peer-reviewed scholarly sources.<br> <br>**1.9 to >1.7 ptsFair** Uses 1-2 number of peer-reviewed scholarly sources; 1-2 number of sources are not scholarly.<br> <br>**1.7 to >0 ptsPoor** Does not use peer-reviewed scholarly sources. | 2.5 pts |
| This criterion is linked to a Learning OutcomeSource Attribution and APA Formatting | **2.5 to >2.2 ptsExcellent** All sources are cited in APA format without any errors. Student work is original– no AI-generated text is presented as student’s own, independent work.<br> <br>**2.2 to >1.9 ptsGood** All sources are cited in APA format with some minor errors. Student work is original– no AI-generated text is presented as student’s own, independent work.<br> <br>**1.9 to >1.7 ptsFair** All sources are cited with frequent APA formatting errors. Student work is original– no AI-generated text is presented as student’s own, independent work.<br> <br>**1.7 to >0 ptsPoor** Missing source citations and/or minimal adherence to APA formatting rules. Student work is not original– AI-generated text is presented as student’s own, independent work. | 2.5 pts |
| This criterion is linked to a Learning OutcomeGrammar, Mechanics, and Punctuation | **2.5 to >2.2 ptsExcellent** Uses correct grammar, spelling, and punctuation with no errors.<br> <br>**2.2 to >1.9 ptsGood** Uses correct grammar, spelling, and punctuation with few errors.<br> <br>**1.9 to >1.7 ptsFair** Uses correct grammar, spelling, and punctuation with frequent errors.<br> <br>**1.7 to >0 ptsPoor** Post contains frequent errors in grammar, spelling, and punctuation that interfere with comprehension. | 2.5 pts |
Total Points: 50
**## pharmwk1rubric.docx**
**NURS_6521_Module1_Assignment1_Rubric**
| | | |
| — | — | — |
| NURS_6521_Module1_Assignment1_Rubric |
| **Criteria** | **Ratings** | **Pts** |
| This criterion is linked to a Learning OutcomeMedication Selection and Personalization | **15 to >13.5 ptsExcellent** Medication choices are thoroughly justified with clear, evidencebased rationale. Demonstrates strong integration of genetics, gender, ethnicity, age, behavior, and pathophysiological factors (e.g., renal/hepatic/cardiac impairment). Personalization is comprehensive and clinically sound.<br> <br>**13.5 to >11.9 ptsGood** Medication choices are appropriate and supported with rationale. Most personalized patient factors are considered, though depth may be limited.<br> <br>**11.9 to >10.4 ptsFair** Medication choices are partially justified; rationale may be vague or incomplete. Limited personalization or missing key factors.<br> <br>**10.4 to >0 ptsPoor** Medication choices are unclear, inappropriate, or unsupported. No meaningful personalization present. | 15 pts |
| This criterion is linked to a Learning OutcomeEthical and Legal Considerations | **12.5 to >11.1 ptsExcellent** Demonstrates sophisticated insight into ethical and legal implications (e.g., prescriptive authority, informed consent, cultural humility, scope of practice). Connections to the case are strong and wellsupported.<br> <br>**11.1 to >9.9 ptsGood** Addresses relevant ethical and legal issues with appropriate detail; some application to the case is evident.<br> <br>**9.9 to >8.6 ptsFair** Mentions ethical and legal considerations, but discussion lacks depth or clear application to the case.<br> <br>**8.6 to >0 ptsPoor** Ethical and legal considerations are inaccurate, missing, or irrelevant. | 12.5 pts |
| This criterion is linked to a Learning OutcomeMedication Orders (Accuracy and Completeness) | **12.5 to >11.1 ptsExcellent** All medication orders are complete, accurate, and written in correct clinical format (drug, dose, route, frequency, duration, special instructions). Orders reflect safe, evidencebased prescribing.<br> <br>**11.1 to >9.9 ptsGood** Orders are mostly correct with minor errors in formatting or specificity. Safe and generally appropriate.<br> <br>**9.9 to >8.6 ptsFair** Orders include several formatting, dosing, or instruction errors. Some concerns about safety or completeness.<br> <br>**8.6 to >0 ptsPoor** Orders are incomplete, incorrect, unsafe, or not in clinical format. | 12.5 pts |
| This criterion is linked to a Learning OutcomeCritical Analysis and Source Integration | **2.5 to >2.2 ptsExcellent** Demonstrates strong critical analysis and synthesis of course concepts and module readings.<br> <br>**2.2 to >1.9 ptsGood** Demonstrates sufficient critical analysis and synthesis of course concepts and module readings.<br> <br>**1.9 to >1.7 ptsFair** Demonstrates minimal critical analysis and synthesis of course concepts and module readings.<br> <br>**1.7 to >0 ptsPoor** Lacks critical analysis and/or synthesis of course concepts and module readings. | 2.5 pts |
| This criterion is linked to a Learning OutcomeNumber and Quality of Sources | **2.5 to >2.2 ptsExcellent** Uses 3 peer-reviewed scholarly sources.<br> <br>**2.2 to >1.9 ptsGood** Uses 2 number of peer-reviewed scholarly sources.<br> <br>**1.9 to >1.7 ptsFair** Uses 1-2 number of peer-reviewed scholarly sources; 1-2 number of sources are not scholarly.<br> <br>**1.7 to >0 ptsPoor** Does not use peer-reviewed scholarly sources. | 2.5 pts |
| This criterion is linked to a Learning OutcomeSource Attribution and APA Formatting | **2.5 to >2.2 ptsExcellent** All sources are cited in APA format without any errors. Student work is original– no AI-generated text is presented as student’s own, independent work.<br> <br>**2.2 to >1.9 ptsGood** All sources are cited in APA format with some minor errors. Student work is original– no AI-generated text is presented as student’s own, independent work.<br> <br>**1.9 to >1.7 ptsFair** All sources are cited with frequent APA formatting errors. Student work is original– no AI-generated text is presented as student’s own, independent work.<br> <br>**1.7 to >0 ptsPoor** Missing source citations and/or minimal adherence to APA formatting rules. Student work is not original– AI-generated text is presented as student’s own, independent work. | 2.5 pts |
| This criterion is linked to a Learning OutcomeGrammar, Mechanics, and Punctuation | **2.5 to >2.2 ptsExcellent** Uses correct grammar, spelling, and punctuation with no errors.<br> <br>**2.2 to >1.9 ptsGood** Uses correct grammar, spelling, and punctuation with few errors.<br> <br>**1.9 to >1.7 ptsFair** Uses correct grammar, spelling, and punctuation with frequent errors.<br> <br>**1.7 to >0 ptsPoor** Post contains frequent errors in grammar, spelling, and punctuation that interfere with comprehension. | 2.5 pts |
Total Points: 50
**## pharmwk1asign.docx**
ASSIGNMENT: CARDIOVASCULAR SYSTEM PATIENT CASE, PART 1
This Assessment invites you to apply your pharmacological knowledge to a real-world scenario. You will be tasked with developing a
**personalized medication plan**, considering factors such as genetics, age, ethnicity, and pathophysiological changes. This assignment emphasizes the importance of ethical and legal considerations in advanced practice, requiring you to
**justify your clinical decisions** and
**write complete medication orders**. The study questions and required readings will serve as essential tools to guide your analysis and support your evidence-based approach.
**Level 1: No AI Permitted**
· AI tools may
**not** be used at any stage
· Common for clinical documentation or performancebased work
RESOURCES
Be sure to review the Learning Resources before completing this assessment.
[Required Resources](https://waldenu.instructure.com/courses/230368/assignments/3290061?module_item_id=9903127)
**To prepare:**
· Complete the Cardiovascular System Patient Case scenario.
· Utilize course resources, clinical practice guidelines, and scholarly sources published within the past 5 years to assist you in completing the cardiovascular system patient case.
· Download the Patient Case Study Template.
BY SUNDAY OF WEEK 1
Complete the Patient Case Study Template. The template will include the following:
· Describe and outline the specific medications you would prescribe for the provided patient. In your description, be sure to consider factors such as genetics, gender, ethnicity, age, behavior, and/or possible pathophysiological changes due to disease (e.g., renal failure, heart failure, liver failure).
· Discuss the ethical and legal considerations of the personalized plan.
· Write a complete medication order for all medications prescribed.
· Use and cite at least three scholarly sources published within the past 5 years, and follow the APA format for in-text citations and reference list.
## image1.png
## image2.png
**## template.docx**
## Patient Case Study Template
### 1. Patient Profile
·
**Age:**
·
**Gender:**
·
**Ethnicity:**
·
**Relevant Genetics (if available):**
·
**Behavioral Factors (e.g., smoking, alcohol, adherence):**
·
**Relevant Medical History:**
·
**Current Diagnoses:**
·
**Pathophysiological Changes (e.g., renal, heart, or liver failure):**
### 2. Medication Plan
Describe and outline the specific medications you would prescribe for the patient. In your description, be sure to consider genetics, gender, ethnicity, age, behavioral factors, and possible pathophysiological changes due to disease.
·
**Medication Name:**
·
**Dosage and Route:**
·
**Frequency:**
·
**Rationale for Selection (including patient-specific factors):**
·
**Potential Drug Interactions or Contraindications:**
·
**Monitoring Parameters:**
### 3. Ethical and Legal Considerations
Discuss any ethical and legal considerations related to the personalized medication plan, including informed consent, patient autonomy, cultural sensitivity, and compliance with relevant laws and guidelines.
### 4. Complete Medication Order
Write a complete and clear medication order for all prescribed medications. Ensure the order includes medication name, dose, route, frequency, and any special instructions.
·
**Medication Name:**
·
**Dose:**
·
**Route:**
·
**Frequency:**
·
**Special Instructions:**
### 5. References
Include at least three scholarly sources (published within the last 5 years) to support your plan. Use proper APA format for both in-text citations and the reference list.
·
**In-text citations example:** (Author, Year)
·
**Reference list example:** Author, A. A., & Author, B. B. (Year). Title of article.
_Title of Journal, volume number_(issue number), page range. [URL]>
**## GOALTotalCholesterol.docx**
**GOAL Total Cholesterol**
The following information will help you understand the critical roles of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) in cardiovascular health. By exploring the mechanisms by which LDL contributes to atherosclerosis and the protective functions of HDL, you will gain insight into the clinical significance of lipid management and current guideline perspectives.
**Why is LDL Harmful?**
The callouts in the picture below explain why LDL is harmful.
**LDL and HDL: Clinical Risk, Guidelines, and Cardiovascular Implications**
Elevated low-density lipoprotein (LDL) levels are directly and dose-dependently associated with increased risk of atherosclerotic cardiovascular disease (ASCVD), prompting clinical guidelines to emphasize aggressive LDL reduction, particularly in high-risk populations. In contrast, high-density lipoprotein (HDL) supports cardiovascular health by facilitating reverse cholesterol transport, removing excess cholesterol from peripheral tissues and promoting its excretion, thereby offering a protective effect against atherosclerosis.
**Clinical Risk Relationship**
Direct, dose-dependent relationship:
· Higher LDL = higher ASCVD risk
· No known “safe” lower threshold
Each ~39 mg/dL (1 mmol/L) LDL reduction lowers major CV events by ~20–25%
**Guideline Perspective**
· ACC/AHA focuses on percent LDL reduction, not absolute targets
· High-risk patients (diabetes, smoking, hypertension, obesity) benefit from aggressive LDL lowering
· LDL ≥190 mg/dL is considered severe hypercholesterolemia
· High-Density Lipoprotein (HDL) participates in reverse cholesterol transport.
**Understanding HDL**
High-density lipoprotein (HDL) plays a crucial role in cardiovascular health by removing cholesterol from arterial walls and macrophages, transporting it back to the liver for excretion, a process known as reverse cholesterol transport. Beyond cholesterol removal, HDL exhibits anti-inflammatory, antioxidant, and endothelial-protective effects, contributing to its atherprotective properties. Clinically, low HDL is recognized as an independent risk marker for atherosclerotic cardiovascular disease (ASCVD), with thresholds defined as less than 40 mg/dL in men and less than 50 mg/dL in women. Low HDL often coexists with other risk factors such as insulin resistance, smoking, obesity, and metabolic syndrome, further elevating ASCVD risk.
PROTECTIVE FUNCTIONS OF HDL
LOW HDL AND RISK
· Removes cholesterol from arterial walls and macrophages
· Transports cholesterol back to the liver for excretion
· Has:
· Anti-inflammatory effects
· Antioxidant properties
· Endothelial-protective actions
Continued
**Cholesterol Management in Patients with High CHD Risk**
In patients with high-risk coronary heart disease (CHD), effective cholesterol management is critical to reducing atherosclerotic cardiovascular disease (ASCVD) risk. St. John’s wort, a commonly used herbal supplement, is a potent inducer of the CYP3A4 enzyme and P-glycoprotein, which significantly increases the metabolism of statins such as atorvastatin, simvastatin, and lovastatin. This induction leads to reduced serum statin concentrations, diminished LDL-lowering efficacy, and a failure to achieve recommended LDL reduction goals. As a result, residual ASCVD risk remains elevated despite apparent adherence to statin therapy. Clinicians should be vigilant about potential drug–herb interactions, especially in high-risk patients, and routinely assess supplement use to ensure optimal statin effectiveness and cardiovascular outcomes.
**CYP3A4 Enzyme Induction → Reduced Statin Levels**
St. John’s wort is a potent inducer of hepatic and intestinal CYP3A4 and P-glycoprotein.
**Statins Affected**
· Atorvastatin
· Simvastatin
· Lovastatin
**Clincal Effect**
· ↑ CYP3A4 activity → increased statin metabolism
· ↓ Statin serum concentration
· ↓ LDL-lowering efficacy
· Failure to reach LDL reduction goals
· ↑ Residual ASCVD risk despite “adherence”
This interaction is especially dangerous in
**high-risk patients**, where aggressive LDL lowering is essential.
Continued
Continued
**Patient Case Scenario**
Complete the patient case scenario by answering clinical questions regarding how you might treat this patient. Use the information and resources presented throughout this activity to help you determine your choices.
Continued
**Case Wrap-Up: Key Takeaways for NP Students (ACC/AHA Focus)**
**LDL Cholesterol Drives ASCVD Risk**
·
**LDL is causal** in atherosclerosis; lowering LDL reduces MI and stroke risk
· In adults
**40–75 with diabetes**, LDL management is
**mandatory**, not optional
·
**High-intensity statin therapy** is indicated when diabetes is accompanied by additional risk factors (e.g., smoking, hypertension, obesity)
**Statin Intensity Matters**
· High-intensity statins aim for
**≥50% LDL reduction**
· Moderate-intensity statins are
**insufficient** in high-risk patients
· Choice of statin should account for
**drug–drug and drug–supplement interactions**
**Herbal Supplements Are Not Benign**
·
**St. John’s wort induces CYP3A4**, reducing effectiveness of several statins
· Reduced statin exposure
**= loss of cardiovascular protection**
· Always ask about
**OTC and herbal products**
**Important Note:**
Supplements can cause therapeutic failure, not just toxicity.
**HDL Is a Risk Marker, Note a Treatment Plan**
· Low HDL increases ASCVD risk but
**raising HDL pharmacologically does not improve outcomes**
· Focus on:
· LDL lowering
· Smoking cessation
· Exercise and weight loss
**Smoking is the Most Dangerous Modifiable Risk Factor**
· Smoking:
· Accelerates atherosclerosis
· Lowers HDL
· Increases LDL oxidation
· Statins cannot fully offset the harm of tobacco use
**Board Tip:** Smoking cessation may reduce ASCVD risk more than any single medication.
**Diabetes = Cardiovascular Disease Risk Equivalent**
· Diabetes dramatically increases ASCVD risk even in younger patients
· GLP-1 receptor agonists (e.g., liraglutide) provide
**cardiovascular benefit**
· Aggressive risk factor modification is required early
**BMI and Lifestyle Changes Are Part of Pharmacotherapy**
· Obesity worsens:
· Dyslipidemia
· Hypertension
· Insulin resistance
· Modest weight loss (5–10%) improves lipid and glycemic control
**Monitoring Is a Safety and Effectiveness Tool**
· Lipid panels are used to assess
**response and adherence**, not just diagnosis
· Follow-up at
**4–12 weeks** after statin initiation is essential
END OF ACTIVITY
## image1.jpeg
## image2.jpeg
**## pharmwk1rubric.docx**
**NURS_6521_Module1_Assignment1_Rubric**
| | | |
| — | — | — |
| NURS_6521_Module1_Assignment1_Rubric |
| **Criteria** | **Ratings** | **Pts** |
| This criterion is linked to a Learning OutcomeMedication Selection and Personalization | **15 to >13.5 ptsExcellent** Medication choices are thoroughly justified with clear, evidencebased rationale. Demonstrates strong integration of genetics, gender, ethnicity, age, behavior, and pathophysiological factors (e.g., renal/hepatic/cardiac impairment). Personalization is comprehensive and clinically sound.<br> <br>**13.5 to >11.9 ptsGood** Medication choices are appropriate and supported with rationale. Most personalized patient factors are considered, though depth may be limited.<br> <br>**11.9 to >10.4 ptsFair** Medication choices are partially justified; rationale may be vague or incomplete. Limited personalization or missing key factors.<br> <br>**10.4 to >0 ptsPoor** Medication choices are unclear, inappropriate, or unsupported. No meaningful personalization present. | 15 pts |
| This criterion is linked to a Learning OutcomeEthical and Legal Considerations | **12.5 to >11.1 ptsExcellent** Demonstrates sophisticated insight into ethical and legal implications (e.g., prescriptive authority, informed consent, cultural humility, scope of practice). Connections to the case are strong and wellsupported.<br> <br>**11.1 to >9.9 ptsGood** Addresses relevant ethical and legal issues with appropriate detail; some application to the case is evident.<br> <br>**9.9 to >8.6 ptsFair** Mentions ethical and legal considerations, but discussion lacks depth or clear application to the case.<br> <br>**8.6 to >0 ptsPoor** Ethical and legal considerations are inaccurate, missing, or irrelevant. | 12.5 pts |
| This criterion is linked to a Learning OutcomeMedication Orders (Accuracy and Completeness) | **12.5 to >11.1 ptsExcellent** All medication orders are complete, accurate, and written in correct clinical format (drug, dose, route, frequency, duration, special instructions). Orders reflect safe, evidencebased prescribing.<br> <br>**11.1 to >9.9 ptsGood** Orders are mostly correct with minor errors in formatting or specificity. Safe and generally appropriate.<br> <br>**9.9 to >8.6 ptsFair** Orders include several formatting, dosing, or instruction errors. Some concerns about safety or completeness.<br> <br>**8.6 to >0 ptsPoor** Orders are incomplete, incorrect, unsafe, or not in clinical format. | 12.5 pts |
| This criterion is linked to a Learning OutcomeCritical Analysis and Source Integration | **2.5 to >2.2 ptsExcellent** Demonstrates strong critical analysis and synthesis of course concepts and module readings.<br> <br>**2.2 to >1.9 ptsGood** Demonstrates sufficient critical analysis and synthesis of course concepts and module readings.<br> <br>**1.9 to >1.7 ptsFair** Demonstrates minimal critical analysis and synthesis of course concepts and module readings.<br> <br>**1.7 to >0 ptsPoor** Lacks critical analysis and/or synthesis of course concepts and module readings. | 2.5 pts |
| This criterion is linked to a Learning OutcomeNumber and Quality of Sources | **2.5 to >2.2 ptsExcellent** Uses 3 peer-reviewed scholarly sources.<br> <br>**2.2 to >1.9 ptsGood** Uses 2 number of peer-reviewed scholarly sources.<br> <br>**1.9 to >1.7 ptsFair** Uses 1-2 number of peer-reviewed scholarly sources; 1-2 number of sources are not scholarly.<br> <br>**1.7 to >0 ptsPoor** Does not use peer-reviewed scholarly sources. | 2.5 pts |
| This criterion is linked to a Learning OutcomeSource Attribution and APA Formatting | **2.5 to >2.2 ptsExcellent** All sources are cited in APA format without any errors. Student work is original– no AI-generated text is presented as student’s own, independent work.<br> <br>**2.2 to >1.9 ptsGood** All sources are cited in APA format with some minor errors. Student work is original– no AI-generated text is presented as student’s own, independent work.<br> <br>**1.9 to >1.7 ptsFair** All sources are cited with frequent APA formatting errors. Student work is original– no AI-generated text is presented as student’s own, independent work.<br> <br>**1.7 to >0 ptsPoor** Missing source citations and/or minimal adherence to APA formatting rules. Student work is not original– AI-generated text is presented as student’s own, independent work. | 2.5 pts |
| This criterion is linked to a Learning OutcomeGrammar, Mechanics, and Punctuation | **2.5 to >2.2 ptsExcellent** Uses correct grammar, spelling, and punctuation with no errors.<br> <br>**2.2 to >1.9 ptsGood** Uses correct grammar, spelling, and punctuation with few errors.<br> <br>**1.9 to >1.7 ptsFair** Uses correct grammar, spelling, and punctuation with frequent errors.<br> <br>**1.7 to >0 ptsPoor** Post contains frequent errors in grammar, spelling, and punctuation that interfere with comprehension. | 2.5 pts |
Total Points: 50
**## pharmwk1asign.docx**
ASSIGNMENT: CARDIOVASCULAR SYSTEM PATIENT CASE, PART 1
This Assessment invites you to apply your pharmacological knowledge to a real-world scenario. You will be tasked with developing a
**personalized medication plan**, considering factors such as genetics, age, ethnicity, and pathophysiological changes. This assignment emphasizes the importance of ethical and legal considerations in advanced practice, requiring you to
**justify your clinical decisions** and
**write complete medication orders**. The study questions and required readings will serve as essential tools to guide your analysis and support your evidence-based approach.
**Level 1: No AI Permitted**
· AI tools may
**not** be used at any stage
· Common for clinical documentation or performancebased work
RESOURCES
Be sure to review the Learning Resources before completing this assessment.
[Required Resources](https://waldenu.instructure.com/courses/230368/assignments/3290061?module_item_id=9903127)
**To prepare:**
· Complete the Cardiovascular System Patient Case scenario.
· Utilize course resources, clinical practice guidelines, and scholarly sources published within the past 5 years to assist you in completing the cardiovascular system patient case.
· Download the Patient Case Study Template.
BY SUNDAY OF WEEK 1
Complete the Patient Case Study Template. The template will include the following:
· Describe and outline the specific medications you would prescribe for the provided patient. In your description, be sure to consider factors such as genetics, gender, ethnicity, age, behavior, and/or possible pathophysiological changes due to disease (e.g., renal failure, heart failure, liver failure).
· Discuss the ethical and legal considerations of the personalized plan.
· Write a complete medication order for all medications prescribed.
· Use and cite at least three scholarly sources published within the past 5 years, and follow the APA format for in-text citations and reference list.
## image1.png
## image2.png
**## template.docx**
## Patient Case Study Template
### 1. Patient Profile
·
**Age:**
·
**Gender:**
·
**Ethnicity:**
·
**Relevant Genetics (if available):**
·
**Behavioral Factors (e.g., smoking, alcohol, adherence):**
·
**Relevant Medical History:**
·
**Current Diagnoses:**
·
**Pathophysiological Changes (e.g., renal, heart, or liver failure):**
### 2. Medication Plan
Describe and outline the specific medications you would prescribe for the patient. In your description, be sure to consider genetics, gender, ethnicity, age, behavioral factors, and possible pathophysiological changes due to disease.
·
**Medication Name:**
·
**Dosage and Route:**
·
**Frequency:**
·
**Rationale for Selection (including patient-specific factors):**
·
**Potential Drug Interactions or Contraindications:**
·
**Monitoring Parameters:**
### 3. Ethical and Legal Considerations
Discuss any ethical and legal considerations related to the personalized medication plan, including informed consent, patient autonomy, cultural sensitivity, and compliance with relevant laws and guidelines.
### 4. Complete Medication Order
Write a complete and clear medication order for all prescribed medications. Ensure the order includes medication name, dose, route, frequency, and any special instructions.
·
**Medication Name:**
·
**Dose:**
·
**Route:**
·
**Frequency:**
·
**Special Instructions:**
### 5. References
Include at least three scholarly sources (published within the last 5 years) to support your plan. Use proper APA format for both in-text citations and the reference list.
·
**In-text citations example:** (Author, Year)
·
**Reference list example:** Author, A. A., & Author, B. B. (Year). Title of article.
_Title of Journal, volume number_(issue number), page range. [URL]>
**## GOALTotalCholesterol.docx**
**GOAL Total Cholesterol**
The following information will help you understand the critical roles of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) in cardiovascular health. By exploring the mechanisms by which LDL contributes to atherosclerosis and the protective functions of HDL, you will gain insight into the clinical significance of lipid management and current guideline perspectives.
**Why is LDL Harmful?**
The callouts in the picture below explain why LDL is harmful.
**LDL and HDL: Clinical Risk, Guidelines, and Cardiovascular Implications**
Elevated low-density lipoprotein (LDL) levels are directly and dose-dependently associated with increased risk of atherosclerotic cardiovascular disease (ASCVD), prompting clinical guidelines to emphasize aggressive LDL reduction, particularly in high-risk populations. In contrast, high-density lipoprotein (HDL) supports cardiovascular health by facilitating reverse cholesterol transport, removing excess cholesterol from peripheral tissues and promoting its excretion, thereby offering a protective effect against atherosclerosis.
**Clinical Risk Relationship**
Direct, dose-dependent relationship:
· Higher LDL = higher ASCVD risk
· No known “safe” lower threshold
Each ~39 mg/dL (1 mmol/L) LDL reduction lowers major CV events by ~20–25%
**Guideline Perspective**
· ACC/AHA focuses on percent LDL reduction, not absolute targets
· High-risk patients (diabetes, smoking, hypertension, obesity) benefit from aggressive LDL lowering
· LDL ≥190 mg/dL is considered severe hypercholesterolemia
· High-Density Lipoprotein (HDL) participates in reverse cholesterol transport.
**Understanding HDL**
High-density lipoprotein (HDL) plays a crucial role in cardiovascular health by removing cholesterol from arterial walls and macrophages, transporting it back to the liver for excretion, a process known as reverse cholesterol transport. Beyond cholesterol removal, HDL exhibits anti-inflammatory, antioxidant, and endothelial-protective effects, contributing to its atherprotective properties. Clinically, low HDL is recognized as an independent risk marker for atherosclerotic cardiovascular disease (ASCVD), with thresholds defined as less than 40 mg/dL in men and less than 50 mg/dL in women. Low HDL often coexists with other risk factors such as insulin resistance, smoking, obesity, and metabolic syndrome, further elevating ASCVD risk.
PROTECTIVE FUNCTIONS OF HDL
LOW HDL AND RISK
· Removes cholesterol from arterial walls and macrophages
· Transports cholesterol back to the liver for excretion
· Has:
· Anti-inflammatory effects
· Antioxidant properties
· Endothelial-protective actions
Continued
**Cholesterol Management in Patients with High CHD Risk**
In patients with high-risk coronary heart disease (CHD), effective cholesterol management is critical to reducing atherosclerotic cardiovascular disease (ASCVD) risk. St. John’s wort, a commonly used herbal supplement, is a potent inducer of the CYP3A4 enzyme and P-glycoprotein, which significantly increases the metabolism of statins such as atorvastatin, simvastatin, and lovastatin. This induction leads to reduced serum statin concentrations, diminished LDL-lowering efficacy, and a failure to achieve recommended LDL reduction goals. As a result, residual ASCVD risk remains elevated despite apparent adherence to statin therapy. Clinicians should be vigilant about potential drug–herb interactions, especially in high-risk patients, and routinely assess supplement use to ensure optimal statin effectiveness and cardiovascular outcomes.
**CYP3A4 Enzyme Induction → Reduced Statin Levels**
St. John’s wort is a potent inducer of hepatic and intestinal CYP3A4 and P-glycoprotein.
**Statins Affected**
· Atorvastatin
· Simvastatin
· Lovastatin
**Clincal Effect**
· ↑ CYP3A4 activity → increased statin metabolism
· ↓ Statin serum concentration
· ↓ LDL-lowering efficacy
· Failure to reach LDL reduction goals
· ↑ Residual ASCVD risk despite “adherence”
This interaction is especially dangerous in
**high-risk patients**, where aggressive LDL lowering is essential.
Continued
Continued
**Patient Case Scenario**
Complete the patient case scenario by answering clinical questions regarding how you might treat this patient. Use the information and resources presented throughout this activity to help you determine your choices.
Continued
**Case Wrap-Up: Key Takeaways for NP Students (ACC/AHA Focus)**
**LDL Cholesterol Drives ASCVD Risk**
·
**LDL is causal** in atherosclerosis; lowering LDL reduces MI and stroke risk
· In adults
**40–75 with diabetes**, LDL management is
**mandatory**, not optional
·
**High-intensity statin therapy** is indicated when diabetes is accompanied by additional risk factors (e.g., smoking, hypertension, obesity)
**Statin Intensity Matters**
· High-intensity statins aim for
**≥50% LDL reduction**
· Moderate-intensity statins are
**insufficient** in high-risk patients
· Choice of statin should account for
**drug–drug and drug–supplement interactions**
**Herbal Supplements Are Not Benign**
·
**St. John’s wort induces CYP3A4**, reducing effectiveness of several statins
· Reduced statin exposure
**= loss of cardiovascular protection**
· Always ask about
**OTC and herbal products**
**Important Note:**
Supplements can cause therapeutic failure, not just toxicity.
**HDL Is a Risk Marker, Note a Treatment Plan**
· Low HDL increases ASCVD risk but
**raising HDL pharmacologically does not improve outcomes**
· Focus on:
· LDL lowering
· Smoking cessation
· Exercise and weight loss
**Smoking is the Most Dangerous Modifiable Risk Factor**
· Smoking:
· Accelerates atherosclerosis
· Lowers HDL
· Increases LDL oxidation
· Statins cannot fully offset the harm of tobacco use
**Board Tip:** Smoking cessation may reduce ASCVD risk more than any single medication.
**Diabetes = Cardiovascular Disease Risk Equivalent**
· Diabetes dramatically increases ASCVD risk even in younger patients
· GLP-1 receptor agonists (e.g., liraglutide) provide
**cardiovascular benefit**
· Aggressive risk factor modification is required early
**BMI and Lifestyle Changes Are Part of Pharmacotherapy**
· Obesity worsens:
· Dyslipidemia
· Hypertension
· Insulin resistance
· Modest weight loss (5–10%) improves lipid and glycemic control
**Monitoring Is a Safety and Effectiveness Tool**
· Lipid panels are used to assess
**response and adherence**, not just diagnosis
· Follow-up at
**4–12 weeks** after statin initiation is essential
END OF ACTIVITY
## image1.jpeg
## image2.jpeg
**## pharmwk1rubric.docx**
**NURS_6521_Module1_Assignment1_Rubric**
| | | |
| — | — | — |
| NURS_6521_Module1_Assignment1_Rubric |
| **Criteria** | **Ratings** | **Pts** |
| This criterion is linked to a Learning OutcomeMedication Selection and Personalization | **15 to >13.5 ptsExcellent** Medication choices are thoroughly justified with clear, evidencebased rationale. Demonstrates strong integration of genetics, gender, ethnicity, age, behavior, and pathophysiological factors (e.g., renal/hepatic/cardiac impairment). Personalization is comprehensive and clinically sound.<br> <br>**13.5 to >11.9 ptsGood** Medication choices are appropriate and supported with rationale. Most personalized patient factors are considered, though depth may be limited.<br> <br>**11.9 to >10.4 ptsFair** Medication choices are partially justified; rationale may be vague or incomplete. Limited personalization or missing key factors.<br> <br>**10.4 to >0 ptsPoor** Medication choices are unclear, inappropriate, or unsupported. No meaningful personalization present. | 15 pts |
| This criterion is linked to a Learning OutcomeEthical and Legal Considerations | **12.5 to >11.1 ptsExcellent** Demonstrates sophisticated insight into ethical and legal implications (e.g., prescriptive authority, informed consent, cultural humility, scope of practice). Connections to the case are strong and wellsupported.<br> <br>**11.1 to >9.9 ptsGood** Addresses relevant ethical and legal issues with appropriate detail; some application to the case is evident.<br> <br>**9.9 to >8.6 ptsFair** Mentions ethical and legal considerations, but discussion lacks depth or clear application to the case.<br> <br>**8.6 to >0 ptsPoor** Ethical and legal considerations are inaccurate, missing, or irrelevant. | 12.5 pts |
| This criterion is linked to a Learning OutcomeMedication Orders (Accuracy and Completeness) | **12.5 to >11.1 ptsExcellent** All medication orders are complete, accurate, and written in correct clinical format (drug, dose, route, frequency, duration, special instructions). Orders reflect safe, evidencebased prescribing.<br> <br>**11.1 to >9.9 ptsGood** Orders are mostly correct with minor errors in formatting or specificity. Safe and generally appropriate.<br> <br>**9.9 to >8.6 ptsFair** Orders include several formatting, dosing, or instruction errors. Some concerns about safety or completeness.<br> <br>**8.6 to >0 ptsPoor** Orders are incomplete, incorrect, unsafe, or not in clinical format. | 12.5 pts |
| This criterion is linked to a Learning OutcomeCritical Analysis and Source Integration | **2.5 to >2.2 ptsExcellent** Demonstrates strong critical analysis and synthesis of course concepts and module readings.<br> <br>**2.2 to >1.9 ptsGood** Demonstrates sufficient critical analysis and synthesis of course concepts and module readings.<br> <br>**1.9 to >1.7 ptsFair** Demonstrates minimal critical analysis and synthesis of course concepts and module readings.<br> <br>**1.7 to >0 ptsPoor** Lacks critical analysis and/or synthesis of course concepts and module readings. | 2.5 pts |
| This criterion is linked to a Learning OutcomeNumber and Quality of Sources | **2.5 to >2.2 ptsExcellent** Uses 3 peer-reviewed scholarly sources.<br> <br>**2.2 to >1.9 ptsGood** Uses 2 number of peer-reviewed scholarly sources.<br> <br>**1.9 to >1.7 ptsFair** Uses 1-2 number of peer-reviewed scholarly sources; 1-2 number of sources are not scholarly.<br> <br>**1.7 to >0 ptsPoor** Does not use peer-reviewed scholarly sources. | 2.5 pts |
| This criterion is linked to a Learning OutcomeSource Attribution and APA Formatting | **2.5 to >2.2 ptsExcellent** All sources are cited in APA format without any errors. Student work is original– no AI-generated text is presented as student’s own, independent work.<br> <br>**2.2 to >1.9 ptsGood** All sources are cited in APA format with some minor errors. Student work is original– no AI-generated text is presented as student’s own, independent work.<br> <br>**1.9 to >1.7 ptsFair** All sources are cited with frequent APA formatting errors. Student work is original– no AI-generated text is presented as student’s own, independent work.<br> <br>**1.7 to >0 ptsPoor** Missing source citations and/or minimal adherence to APA formatting rules. Student work is not original– AI-generated text is presented as student’s own, independent work. | 2.5 pts |
| This criterion is linked to a Learning OutcomeGrammar, Mechanics, and Punctuation | **2.5 to >2.2 ptsExcellent** Uses correct grammar, spelling, and punctuation with no errors.<br> <br>**2.2 to >1.9 ptsGood** Uses correct grammar, spelling, and punctuation with few errors.<br> <br>**1.9 to >1.7 ptsFair** Uses correct grammar, spelling, and punctuation with frequent errors.<br> <br>**1.7 to >0 ptsPoor** Post contains frequent errors in grammar, spelling, and punctuation that interfere with comprehension. | 2.5 pts |
Total Points: 50